Program
berobenatide
Also written as “Berobenatide”, “PF-08653944” and “MET097”.
In Pfizer's pipeline, GLP-1 receptor agonist
. Its studies are mostly in Obesity · Urinary Incontinence, Stress · Sleep Apnea, Obstructive · Sleep Apnea Syndromes · Diabetes Mellitus, Type 2, led by Pfizer.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 2317 open or running | phase 3since Dec 29, 2025 | Nov 27, 2024 | Jan 27, 2027phase 1 · NCT07508241 |
- Named in Pfizer’s own pipeline as
berobenatide PF-08653944
, phase 3, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 27, 2024.
- Mar 13, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT06897202 · 133 enrolled · United States
- Apr 3, 2025Phase 2 study in ObesityNCT06924320 · 201 enrolled · United States
- May 6, 2025Phase 2 study in ObesityNCT06973720 · 268 enrolled · United States
- Dec 29, 2025Phase 3 study in ObesityPhase 3 reachedNCT07311850 · 3,578 enrolled · United States, Bulgaria, Canada and more
- Feb 3, 2026Phase 1 study in OverweightNCT07400679 · 48 enrolled · United States
- Feb 3, 2026Phase 3 study in ObesityNCT07400653 · 1,078 enrolled · United States, Argentina, Bulgaria and more
- Mar 27, 2026Phase 1 study in ObesityNCT07508241 · 22 enrolled · United States
- Apr 2, 2026Phase 1 study in HealthyNCT07519135 · 26 planned · United States
- May 12, 2026Phase 3 study in ObesityNCT07595549 · 954 planned · United States, Brazil, Canada and more
- Aug 25, 20263 phase 3 studies in ObesityNCT07792954, NCT07794774, NCT07794761
- Sep 11, 20263 phase 3 studiesNCT07823608, NCT07845500, NCT07874633
- Sep 22, 2026Phase 1 study in OverweightNCT07845513 · 11 enrolled · China
- Oct 9, 20264 phase 3 studiesNCT07881757, NCT07919678, NCT07915609 and 1 more
- Oct 9, 2026Phase 1 study in OverweightNCT07876531 · 144 planned · United States
Ahead
- Jan 27, 2027Primary completion: phase 1 study in ObesityNCT07508241
- Feb 21, 2027Primary completion: phase 1 study in OverweightNCT07845513
- Apr 6, 2027Primary completion: phase 1 study in OverweightNCT07876531
- Jul 9, 2027Primary completion: phase 1 study in HealthyNCT07519135
TargetBeta
“GLP-1 receptor agonist”the company's pipeline, read by Claude · source
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
| efpeglenatiderule | Hanmi Pharmaceutical | phase 3 | 13 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07932925Urinary Incontinence, Stress | 3 | Not yet recruiting | Oct 13, 2028 | 900 |
| NCT07919678Obesity · United States, Canada | 3 | Recruiting | Aug 22, 2028 | 656 |
| NCT07915609Obesity · United States | 3 | Recruiting | Aug 21, 2028 | 756 |
| NCT07881757Apnea · United States | 3 | Recruiting | Jun 1, 2028 | 258 |
| NCT07876531Overweight · United States | 1 | Recruiting | Apr 6, 2027 | 144 |
| NCT07874633Obesity · China | 3 | Recruiting | Jun 6, 2028 | 432 |
| NCT07845513Overweight · China | 1 | Active, not recruiting | Feb 21, 2027 | 11 |
| NCT07845500Obesity · United States, Australia | 3 | Recruiting | Feb 16, 2028 | 660 |
| NCT07823608Apnea · United States | 3 | Recruiting | Apr 30, 2028 | 258 |
| NCT07794774Obesity · Japan | 3 | Recruiting | Feb 21, 2029 | 197 |
| NCT07794761Obesity · Japan | 3 | Recruiting | Mar 14, 2029 | 180 |
| NCT07792954Obesity · China | 3 | Recruiting | Mar 14, 2028 | 300 |
| NCT07595549Obesity · United States, Brazil, Canada and more | 3 | Recruiting | May 4, 2028 | 954 |
| NCT07519135Healthy · United States | 1 | Recruiting | Jul 9, 2027 | 26 |
| NCT07508241Obesity · United States | 1 | Active, not recruiting | Jan 27, 2027 | 22 |
| NCT07400679Overweight · United States | 1 | Completed | Jul 2, 2026 | 48 |
| NCT07400653Obesity · United States, Argentina, Bulgaria and more | 3 | Active, not recruiting | Oct 12, 2027 | 1,078 |
| NCT07311850Obesity · United States, Bulgaria, Canada and more | 3 | Active, not recruiting | Sep 21, 2027 | 3,578 |
| NCT06973720Obesity · United States | 2 | Completed | Dec 16, 2025 | 268 |
| NCT06924320Obesity · United States | 2 | Completed | Sep 29, 2026 | 201 |
| NCT06897202Diabetes Mellitus, Type 2 · United States | 2 | Completed | Dec 29, 2025 | 133 |
| NCT06857617Obesity · United States | 2 | Completed | Jan 3, 2025 | 120 |
| NCT06712836Obesity · United States | 2 | Completed | Jul 3, 2025 | 239 |
How it is read
Names in the registry
- “Berobenatide”, 11 entries
- “PF-08653944”, 6 entries
- “MET097”, 4 entries
- “MET097 Injection”, 1 entry
- “(Part C) MET097”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 18 studies
- Urinary Incontinence, Stress, 1 study
- Sleep Apnea, Obstructive, 1 study
- Sleep Apnea Syndromes, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.